APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Atrophic Vaginitis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Atrophic Vaginitis Treatment Market Analysis and Forecast 2026-2032

Report ID 173968120221 December 2025196 pages

Choose your research edition.

Industry ResearchAtrophic Vaginitis Treatment Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Atrophic Vaginitis Treatment Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Atrophic Vaginitis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Atrophic Vaginitis Treatment Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Atrophic Vaginitis Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Atrophic Vaginitis Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Atrophic Vaginitis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Atrophic Vaginitis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Atrophic Vaginitis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Atrophic Vaginitis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Atrophic Vaginitis Treatment include Bayer HealthCare Pharmaceuticals Inc, Theramex, Shionogi, Pantarhei Bioscience, Mithra Pharmaceuticals, Hormos Medical, Endoceutics, Duchesnay and AMAG Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Atrophic Vaginitis Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Atrophic Vaginitis Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Atrophic Vaginitis Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Atrophic Vaginitis Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Atrophic Vaginitis Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Atrophic Vaginitis Treatment revenue, projected growth trends, production technology, application and end-user industry.

Atrophic Vaginitis Treatment Segment by Company

Bayer HealthCare Pharmaceuticals Inc

Theramex

Shionogi

Pantarhei Bioscience

Mithra Pharmaceuticals

Hormos Medical

Endoceutics

Duchesnay

AMAG Pharmaceuticals

Atrophic Vaginitis Treatment Segment by Type

Vaginal Moisturizers

Water-based Lubricants

Atrophic Vaginitis Treatment Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Atrophic Vaginitis Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atrophic Vaginitis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Atrophic Vaginitis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atrophic Vaginitis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Atrophic Vaginitis Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Atrophic Vaginitis Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Atrophic Vaginitis Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Atrophic Vaginitis Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Vaginal Moisturizers Major Player Table 3. Water-based Lubricants Major Player Table 4. Global Atrophic Vaginitis Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Retail Pharmacy Major Player Table 6. Online Pharmacy Major Player Table 7. Hospital Pharmacy Major Player Table 8. Atrophic Vaginitis Treatment Industry Trends Table 9. Atrophic Vaginitis Treatment Industry Drivers Table 10. Atrophic Vaginitis Treatment Industry Opportunities and Challenges Table 11. Atrophic Vaginitis Treatment Industry Restraints Table 12. Global Atrophic Vaginitis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Atrophic Vaginitis Treatment Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Atrophic Vaginitis Treatment Market Share by Region (2021-2026) Table 15. Global Atrophic Vaginitis Treatment Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Atrophic Vaginitis Treatment Market Share by Region (2027-2032) Table 17. Global Atrophic Vaginitis Treatment Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Atrophic Vaginitis Treatment Revenue Market Share by Players (2021-2026) Table 19. Global Atrophic Vaginitis Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Atrophic Vaginitis Treatment Key Players Headquarters & Area Served Table 21. Global Atrophic Vaginitis Treatment Players, Product Type & Application Table 22. Global Atrophic Vaginitis Treatment Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Atrophic Vaginitis Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Atrophic Vaginitis Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Atrophic Vaginitis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Atrophic Vaginitis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Atrophic Vaginitis Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Atrophic Vaginitis Treatment Revenue Market Share by Type (2027-2032) Table 30. Global Atrophic Vaginitis Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Atrophic Vaginitis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Atrophic Vaginitis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Atrophic Vaginitis Treatment Revenue Market Share by Application (2021-2026) Table 34. Global Atrophic Vaginitis Treatment Revenue Market Share by Application (2027-2032) Table 35. Bayer HealthCare Pharmaceuticals Inc Company Information Table 36. Bayer HealthCare Pharmaceuticals Inc Business Overview Table 37. Bayer HealthCare Pharmaceuticals Inc Atrophic Vaginitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Bayer HealthCare Pharmaceuticals Inc Atrophic Vaginitis Treatment Product Portfolio Table 39. Bayer HealthCare Pharmaceuticals Inc Recent Development Table 40. Theramex Company Information Table 41. Theramex Business Overview Table 42. Theramex Atrophic Vaginitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Theramex Atrophic Vaginitis Treatment Product Portfolio Table 44. Theramex Recent Development Table 45. Shionogi Company Information Table 46. Shionogi Business Overview Table 47. Shionogi Atrophic Vaginitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Shionogi Atrophic Vaginitis Treatment Product Portfolio Table 49. Shionogi Recent Development Table 50. Pantarhei Bioscience Company Information Table 51. Pantarhei Bioscience Business Overview Table 52. Pantarhei Bioscience Atrophic Vaginitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Pantarhei Bioscience Atrophic Vaginitis Treatment Product Portfolio Table 54. Pantarhei Bioscience Recent Development Table 55. Mithra Pharmaceuticals Company Information Table 56. Mithra Pharmaceuticals Business Overview Table 57. Mithra Pharmaceuticals Atrophic Vaginitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Mithra Pharmaceuticals Atrophic Vaginitis Treatment Product Portfolio Table 59. Mithra Pharmaceuticals Recent Development Table 60. Hormos Medical Company Information Table 61. Hormos Medical Business Overview Table 62. Hormos Medical Atrophic Vaginitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Hormos Medical Atrophic Vaginitis Treatment Product Portfolio Table 64. Hormos Medical Recent Development Table 65. Endoceutics Company Information Table 66. Endoceutics Business Overview Table 67. Endoceutics Atrophic Vaginitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Endoceutics Atrophic Vaginitis Treatment Product Portfolio Table 69. Endoceutics Recent Development Table 70. Duchesnay Company Information Table 71. Duchesnay Business Overview Table 72. Duchesnay Atrophic Vaginitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Duchesnay Atrophic Vaginitis Treatment Product Portfolio Table 74. Duchesnay Recent Development Table 75. AMAG Pharmaceuticals Company Information Table 76. AMAG Pharmaceuticals Business Overview Table 77. AMAG Pharmaceuticals Atrophic Vaginitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. AMAG Pharmaceuticals Atrophic Vaginitis Treatment Product Portfolio Table 79. AMAG Pharmaceuticals Recent Development Table 80. North America Atrophic Vaginitis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 81. North America Atrophic Vaginitis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 82. North America Atrophic Vaginitis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 83. North America Atrophic Vaginitis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 84. North America Atrophic Vaginitis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. North America Atrophic Vaginitis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 86. North America Atrophic Vaginitis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 87. Europe Atrophic Vaginitis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 88. Europe Atrophic Vaginitis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 89. Europe Atrophic Vaginitis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 90. Europe Atrophic Vaginitis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 91. Europe Atrophic Vaginitis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. Europe Atrophic Vaginitis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 93. Europe Atrophic Vaginitis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 94. China Atrophic Vaginitis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 95. China Atrophic Vaginitis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 96. China Atrophic Vaginitis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 97. China Atrophic Vaginitis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia Atrophic Vaginitis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 99. Asia Atrophic Vaginitis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 100. Asia Atrophic Vaginitis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 101. Asia Atrophic Vaginitis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia Atrophic Vaginitis Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Asia Atrophic Vaginitis Treatment Revenue by Region (US$ Million) & (2021-2026) Table 104. Asia Atrophic Vaginitis Treatment Revenue by Region (US$ Million) & (2027-2032) Table 105. SAMEA Atrophic Vaginitis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 106. SAMEA Atrophic Vaginitis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 107. SAMEA Atrophic Vaginitis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 108. SAMEA Atrophic Vaginitis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 109. SAMEA Atrophic Vaginitis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. SAMEA Atrophic Vaginitis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 111. SAMEA Atrophic Vaginitis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Atrophic Vaginitis Treatment Image Figure 2. Global Atrophic Vaginitis Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Atrophic Vaginitis Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Vaginal Moisturizers Image Figure 5. Water-based Lubricants Image Figure 6. Global Atrophic Vaginitis Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Atrophic Vaginitis Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 8. Retail Pharmacy Image Figure 9. Online Pharmacy Image Figure 10. Hospital Pharmacy Image Figure 11. Global Atrophic Vaginitis Treatment Market Size (US$ Million) & (2021-2032) Figure 12. Global Atrophic Vaginitis Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Atrophic Vaginitis Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Atrophic Vaginitis Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Atrophic Vaginitis Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Atrophic Vaginitis Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Atrophic Vaginitis Treatment Revenue Market Share by Type (2021-2032) Figure 19. Global Atrophic Vaginitis Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Atrophic Vaginitis Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Atrophic Vaginitis Treatment Revenue Market Share by Application (2021-2032) Figure 22. North America Atrophic Vaginitis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Atrophic Vaginitis Treatment Revenue Share by Type (2021-2032) Figure 24. North America Atrophic Vaginitis Treatment Revenue Share by Application (2021-2032) Figure 25. North America Atrophic Vaginitis Treatment Revenue Share by Country (2021-2032) Figure 26. United States Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Atrophic Vaginitis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Atrophic Vaginitis Treatment Revenue Share by Type (2021-2032) Figure 31. Europe Atrophic Vaginitis Treatment Revenue Share by Application (2021-2032) Figure 32. Europe Atrophic Vaginitis Treatment Revenue Share by Country (2021-2032) Figure 33. Germany Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Atrophic Vaginitis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Atrophic Vaginitis Treatment Revenue Share by Type (2021-2032) Figure 43. China Atrophic Vaginitis Treatment Revenue Share by Application (2021-2032) Figure 44. Asia Atrophic Vaginitis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Atrophic Vaginitis Treatment Revenue Share by Type (2021-2032) Figure 46. Asia Atrophic Vaginitis Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Atrophic Vaginitis Treatment Revenue Share by Region (2021-2032) Figure 48. Japan Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Atrophic Vaginitis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Atrophic Vaginitis Treatment Revenue Share by Type (2021-2032) Figure 56. SAMEA Atrophic Vaginitis Treatment Revenue Share by Application (2021-2032) Figure 57. SAMEA Atrophic Vaginitis Treatment Revenue Share by Country (2021-2032) Figure 58. Brazil Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Atrophic Vaginitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Vaginal Moisturizers
  • Water-based Lubricants
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
Companies covered
  • Bayer HealthCare Pharmaceuticals Inc
  • Theramex
  • Shionogi
  • Pantarhei Bioscience
  • Mithra Pharmaceuticals
  • Hormos Medical
  • Endoceutics
  • Duchesnay
  • AMAG Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Atrophic Vaginitis Treatment Market by Type
  3. 1.2.1 Global Atrophic Vaginitis Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Vaginal Moisturizers
  5. 1.2.3 Water-based Lubricants
  6. 1.3 Atrophic Vaginitis Treatment Market by Application
  7. 1.3.1 Global Atrophic Vaginitis Treatment Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Retail Pharmacy
  9. 1.3.3 Online Pharmacy
  10. 1.3.4 Hospital Pharmacy
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Atrophic Vaginitis Treatment Market Dynamics
  1. 2.1 Atrophic Vaginitis Treatment Industry Trends
  2. 2.2 Atrophic Vaginitis Treatment Industry Drivers
  3. 2.3 Atrophic Vaginitis Treatment Industry Opportunities and Challenges
  4. 2.4 Atrophic Vaginitis Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Atrophic Vaginitis Treatment Market Perspective (2021-2032)
  2. 3.2 Global Atrophic Vaginitis Treatment Growth Trends by Region
  3. 3.2.1 Global Atrophic Vaginitis Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Atrophic Vaginitis Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Atrophic Vaginitis Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Atrophic Vaginitis Treatment Revenue by Players
  2. 4.1.1 Global Atrophic Vaginitis Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Atrophic Vaginitis Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Atrophic Vaginitis Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Atrophic Vaginitis Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Atrophic Vaginitis Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Atrophic Vaginitis Treatment Players, Product Type & Application
  8. 4.5 Global Atrophic Vaginitis Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Atrophic Vaginitis Treatment Market CR5 and HHI
  11. 4.6.3 2025 Atrophic Vaginitis Treatment Tier 1, Tier 2, and Tier 3
5 Atrophic Vaginitis Treatment Market Size by Type
  1. 5.1 Global Atrophic Vaginitis Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Atrophic Vaginitis Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Atrophic Vaginitis Treatment Revenue Market Share by Type (2021-2032)
6 Atrophic Vaginitis Treatment Market Size by Application
  1. 6.1 Global Atrophic Vaginitis Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Atrophic Vaginitis Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Atrophic Vaginitis Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bayer HealthCare Pharmaceuticals Inc
  2. 7.1.1 Bayer HealthCare Pharmaceuticals Inc Company Information
  3. 7.1.2 Bayer HealthCare Pharmaceuticals Inc Business Overview
  4. 7.1.3 Bayer HealthCare Pharmaceuticals Inc Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bayer HealthCare Pharmaceuticals Inc Atrophic Vaginitis Treatment Product Portfolio
  6. 7.1.5 Bayer HealthCare Pharmaceuticals Inc Recent Developments
  7. 7.2 Theramex
  8. 7.2.1 Theramex Company Information
  9. 7.2.2 Theramex Business Overview
  10. 7.2.3 Theramex Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Theramex Atrophic Vaginitis Treatment Product Portfolio
  12. 7.2.5 Theramex Recent Developments
  13. 7.3 Shionogi
  14. 7.3.1 Shionogi Company Information
  15. 7.3.2 Shionogi Business Overview
  16. 7.3.3 Shionogi Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Shionogi Atrophic Vaginitis Treatment Product Portfolio
  18. 7.3.5 Shionogi Recent Developments
  19. 7.4 Pantarhei Bioscience
  20. 7.4.1 Pantarhei Bioscience Company Information
  21. 7.4.2 Pantarhei Bioscience Business Overview
  22. 7.4.3 Pantarhei Bioscience Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pantarhei Bioscience Atrophic Vaginitis Treatment Product Portfolio
  24. 7.4.5 Pantarhei Bioscience Recent Developments
  25. 7.5 Mithra Pharmaceuticals
  26. 7.5.1 Mithra Pharmaceuticals Company Information
  27. 7.5.2 Mithra Pharmaceuticals Business Overview
  28. 7.5.3 Mithra Pharmaceuticals Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Mithra Pharmaceuticals Atrophic Vaginitis Treatment Product Portfolio
  30. 7.5.5 Mithra Pharmaceuticals Recent Developments
  31. 7.6 Hormos Medical
  32. 7.6.1 Hormos Medical Company Information
  33. 7.6.2 Hormos Medical Business Overview
  34. 7.6.3 Hormos Medical Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Hormos Medical Atrophic Vaginitis Treatment Product Portfolio
  36. 7.6.5 Hormos Medical Recent Developments
  37. 7.7 Endoceutics
  38. 7.7.1 Endoceutics Company Information
  39. 7.7.2 Endoceutics Business Overview
  40. 7.7.3 Endoceutics Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Endoceutics Atrophic Vaginitis Treatment Product Portfolio
  42. 7.7.5 Endoceutics Recent Developments
  43. 7.8 Duchesnay
  44. 7.8.1 Duchesnay Company Information
  45. 7.8.2 Duchesnay Business Overview
  46. 7.8.3 Duchesnay Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Duchesnay Atrophic Vaginitis Treatment Product Portfolio
  48. 7.8.5 Duchesnay Recent Developments
  49. 7.9 AMAG Pharmaceuticals
  50. 7.9.1 AMAG Pharmaceuticals Company Information
  51. 7.9.2 AMAG Pharmaceuticals Business Overview
  52. 7.9.3 AMAG Pharmaceuticals Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 AMAG Pharmaceuticals Atrophic Vaginitis Treatment Product Portfolio
  54. 7.9.5 AMAG Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Atrophic Vaginitis Treatment Revenue (2021-2032)
  2. 8.2 North America Atrophic Vaginitis Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Atrophic Vaginitis Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Atrophic Vaginitis Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Atrophic Vaginitis Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Atrophic Vaginitis Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Atrophic Vaginitis Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Atrophic Vaginitis Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Atrophic Vaginitis Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Atrophic Vaginitis Treatment Revenue by Country
  11. 8.6.1 North America Atrophic Vaginitis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Atrophic Vaginitis Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Atrophic Vaginitis Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Atrophic Vaginitis Treatment Revenue (2021-2032)
  2. 9.2 Europe Atrophic Vaginitis Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Atrophic Vaginitis Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Atrophic Vaginitis Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Atrophic Vaginitis Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Atrophic Vaginitis Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Atrophic Vaginitis Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Atrophic Vaginitis Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Atrophic Vaginitis Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Atrophic Vaginitis Treatment Revenue by Country
  11. 9.6.1 Europe Atrophic Vaginitis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Atrophic Vaginitis Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Atrophic Vaginitis Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Atrophic Vaginitis Treatment Revenue (2021-2032)
  2. 10.2 China Atrophic Vaginitis Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Atrophic Vaginitis Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Atrophic Vaginitis Treatment Revenue by Type (2027-2032)
  5. 10.3 China Atrophic Vaginitis Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Atrophic Vaginitis Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Atrophic Vaginitis Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Atrophic Vaginitis Treatment Revenue by Application (2027-2032)
  9. 10.5 China Atrophic Vaginitis Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Atrophic Vaginitis Treatment Revenue (2021-2032)
  2. 11.2 Asia Atrophic Vaginitis Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Atrophic Vaginitis Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Atrophic Vaginitis Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Atrophic Vaginitis Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Atrophic Vaginitis Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Atrophic Vaginitis Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Atrophic Vaginitis Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Atrophic Vaginitis Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Atrophic Vaginitis Treatment Revenue by Country
  11. 11.6.1 Asia Atrophic Vaginitis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Atrophic Vaginitis Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Atrophic Vaginitis Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Atrophic Vaginitis Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Atrophic Vaginitis Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Atrophic Vaginitis Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Atrophic Vaginitis Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Atrophic Vaginitis Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Atrophic Vaginitis Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Atrophic Vaginitis Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Atrophic Vaginitis Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Atrophic Vaginitis Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Atrophic Vaginitis Treatment Revenue by Country
  11. 12.6.1 SAMEA Atrophic Vaginitis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Atrophic Vaginitis Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Atrophic Vaginitis Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst